Phase 2 study of oregovomab and PLD in patients resistant to platinum and PARPi

• ClinicalTrials.gov ID
• NCT05183984
• Sponsor
• ARCAGY/ GINECO GROUP
• Information Provided By
• ARCAGY/ GINECO GROUP (Responsible Party)
• Last Update Posted
• 2024-01-30

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

• ClinicalTrials.gov ID
• NCT05092360
• Sponsor
• Alkermes, Inc.
• Information Provided By
• Alkermes, Inc. (Responsible Party)
• Last Update Posted
• 2023-09-01
• Current Status
• Recruiting

A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab tazevibulin (STRO-002) versus Investigator’s Choice (IC) Chemotherapy in Women with Relapsed Platinum‑resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)

• ClinicalTrials.gov ID
• NCT03748186
• Sponsor
• Sutro Biopharma, Inc.
• Information Provided By
• Sutro Biopharma, Inc. (Responsible Party)
• Last Update Posted
• 2023-02-09

A Phase 3 Study of Relacorilant in Combination with Nab‑Paclitaxel versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (ROSELLA)

• ClinicalTrials.gov ID
• NCT05257408
• Sponsor
• Corcept Therapeutics
• Information Provided By
• Corcept Therapeutics (Responsible Party)
• Last Update Posted
• 2024-03-12

Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line (DOMENICA)

• ClinicalTrials.gov ID
• NCT05201547
• Sponsor
• ARCAGY/ GINECO GROUP
• Information Provided By
• ARCAGY/ GINECO GROUP (Responsible Party)
• Last Update Posted
• 2023-12-28
• Current Status
• Set Up